FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096997298> ?p ?o ?g. }

• W3096997298 abstract "A randomized controlled pilot trial was conducted to assess if melanoma patients treated with immunotherapy had the number of grade 3 or 4 adverse events during treatment reduced by 50% using a tailored electronic patient-reported outcomes tool in addition to standard toxicity monitoring compared to standard monitoring alone. Secondary endpoints were: if more AEs were reported in the intervention group, if there was a difference between the two groups in the number of telephone consultations, extra out-patient visits, number of days in the hospital, days in steroid treatment and the time patients experienced grade 2 or higher toxicity.Melanoma patients receiving immunotherapy at the Department of Oncology, Odense University Hospital, Denmark participated. Standard care included assessment of AEs by a clinician before each treatment cycle using the Common Terminology Criteria for Adverse Events. In addition, patients randomized to the intervention reported their AEs weekly by an electronic PRO-tool based on the PRO-CTCAE platform.One hundred forty-six melanoma patients were randomized. In this study, we did not detect a difference between the two groups in the number of grade 3 or 4 AEs (P = 0.983), in the overall number of AEs (P = 0.560) or in the time the patients in the two groups experienced grade 2 or higher toxicity (0.516). The number of phone contacts was significantly higher in the intervention group (P = 0.009) and there was a tendency towards patients in the intervention group having more extra visits (P = 0.156).It has been examined if the number of severe AEs for melanoma patients receiving immunotherapy could be reduced by involving the patients in the reporting of symptoms. The results do not justify the expansion of the pilot study into a regular phase III study with this particular set-up. However, a significant difference in the number of phone contacts was found as patients in the intervention group called more frequently, indicating that their attention to AEs was increased. Even though the use of an electronic PRO tool could not reduce the number of severe AEs in this melanoma population, a positive impact on other endpoints such as QoL, communication, or treatment-planning, cannot be excluded.Clinicaltrials.gov NCT03073031 Registered 8 March 2017, Retrospectively registered." @default.
• W3096997298 created "2020-11-09" @default.
• W3096997298 creator A5006781034 @default.
• W3096997298 creator A5050798633 @default.
• W3096997298 creator A5051671663 @default.
• W3096997298 creator A5057277696 @default.
• W3096997298 creator A5064013843 @default.
• W3096997298 creator A5086820712 @default.
• W3096997298 date "2020-10-30" @default.
• W3096997298 modified "2023-10-18" @default.
• W3096997298 title "The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial" @default.
• W3096997298 cites W1526986033 @default.
• W3096997298 cites W1809627231 @default.
• W3096997298 cites W2066560209 @default.
• W3096997298 cites W2066717393 @default.
• W3096997298 cites W2068382224 @default.
• W3096997298 cites W2097995306 @default.
• W3096997298 cites W2103906794 @default.
• W3096997298 cites W2107484016 @default.
• W3096997298 cites W2108052506 @default.
• W3096997298 cites W2112069616 @default.
• W3096997298 cites W2113464761 @default.
• W3096997298 cites W2128035403 @default.
• W3096997298 cites W2128758225 @default.
• W3096997298 cites W2135001286 @default.
• W3096997298 cites W2138013284 @default.
• W3096997298 cites W2152897456 @default.
• W3096997298 cites W2166662937 @default.
• W3096997298 cites W2195040438 @default.
• W3096997298 cites W2289841322 @default.
• W3096997298 cites W2295193139 @default.
• W3096997298 cites W2336689415 @default.
• W3096997298 cites W2347141054 @default.
• W3096997298 cites W2412250098 @default.
• W3096997298 cites W2519279652 @default.
• W3096997298 cites W2560367415 @default.
• W3096997298 cites W2572174216 @default.
• W3096997298 cites W2600291454 @default.
• W3096997298 cites W2606041829 @default.
• W3096997298 cites W2620925856 @default.
• W3096997298 cites W2736166064 @default.
• W3096997298 cites W2752227448 @default.
• W3096997298 cites W2805103957 @default.
• W3096997298 cites W2906673608 @default.
• W3096997298 cites W2925280975 @default.
• W3096997298 cites W2940759533 @default.
• W3096997298 cites W2942600288 @default.
• W3096997298 cites W2944880606 @default.
• W3096997298 cites W2964599082 @default.
• W3096997298 cites W3002564544 @default.
• W3096997298 cites W4319425399 @default.
• W3096997298 doi "https://doi.org/10.1186/s41687-020-00255-0" @default.
• W3096997298 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7599285" @default.
• W3096997298 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33125537" @default.
• W3096997298 hasPublicationYear "2020" @default.
• W3096997298 type Work @default.
• W3096997298 sameAs 3096997298 @default.
• W3096997298 citedByCount "15" @default.
• W3096997298 countsByYear W30969972982021 @default.
• W3096997298 countsByYear W30969972982022 @default.
• W3096997298 countsByYear W30969972982023 @default.
• W3096997298 crossrefType "journal-article" @default.
• W3096997298 hasAuthorship W3096997298A5006781034 @default.
• W3096997298 hasAuthorship W3096997298A5050798633 @default.
• W3096997298 hasAuthorship W3096997298A5051671663 @default.
• W3096997298 hasAuthorship W3096997298A5057277696 @default.
• W3096997298 hasAuthorship W3096997298A5064013843 @default.
• W3096997298 hasAuthorship W3096997298A5086820712 @default.
• W3096997298 hasBestOaLocation W30969972981 @default.
• W3096997298 hasConcept C126322002 @default.
• W3096997298 hasConcept C168563851 @default.
• W3096997298 hasConcept C197934379 @default.
• W3096997298 hasConcept C204243189 @default.
• W3096997298 hasConcept C2777658100 @default.
• W3096997298 hasConcept C2777793932 @default.
• W3096997298 hasConcept C29730261 @default.
• W3096997298 hasConcept C502942594 @default.
• W3096997298 hasConcept C71924100 @default.
• W3096997298 hasConceptScore W3096997298C126322002 @default.
• W3096997298 hasConceptScore W3096997298C168563851 @default.
• W3096997298 hasConceptScore W3096997298C197934379 @default.
• W3096997298 hasConceptScore W3096997298C204243189 @default.
• W3096997298 hasConceptScore W3096997298C2777658100 @default.
• W3096997298 hasConceptScore W3096997298C2777793932 @default.
• W3096997298 hasConceptScore W3096997298C29730261 @default.
• W3096997298 hasConceptScore W3096997298C502942594 @default.
• W3096997298 hasConceptScore W3096997298C71924100 @default.
• W3096997298 hasFunder F4320310455 @default.
• W3096997298 hasIssue "1" @default.
• W3096997298 hasLocation W30969972981 @default.
• W3096997298 hasLocation W30969972982 @default.
• W3096997298 hasLocation W30969972983 @default.
• W3096997298 hasLocation W30969972984 @default.
• W3096997298 hasLocation W30969972985 @default.
• W3096997298 hasOpenAccess W3096997298 @default.
• W3096997298 hasPrimaryLocation W30969972981 @default.
• W3096997298 hasRelatedWork W2137935439 @default.
• W3096997298 hasRelatedWork W2299753147 @default.
• W3096997298 hasRelatedWork W2898543788 @default.
• W3096997298 hasRelatedWork W3007985759 @default.

• next